Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
27 août 2024 03h05 HE
|
Boehringer Ingelheim
Data from the phase Ib Beamion LUNG-1 trial selected for late-breaking oral presentation in the Presidential Symposium at WCLC on Monday, September 9. The U.S. FDA and China's CDE have granted...
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
29 juil. 2024 02h05 HE
|
Boehringer Ingelheim
The CHMP positive opinion is based on the EFFISAYIL® 2 trial, which showed that no flares were observed after week 4 of SPEVIGO® administered subcutaneously. During the 48-week trial, an 84% reduction...
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
18 juil. 2024 03h05 HE
|
Boehringer Ingelheim
Milestones reached in cardiovascular, renal, metabolic health (CRM), and oncologyFurther data read-outs expected in 2024 in oncology, mental health, and pulmonary fibrosisStrong first half net sales...
Boehringer Ingelheim produces its own green energy
08 juil. 2024 13h15 HE
|
Boehringer Ingelheim
German Vice Chancellor and Federal Minister of Economics Robert Habeck inaugurates new biomass power plantIngelheim site can cover 95% of its energy needs from renewable sourcesNew power plant helps...
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
07 juin 2024 04h30 HE
|
Boehringer Ingelheim
News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH)...
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
28 mai 2024 07h00 HE
|
Boehringer Ingelheim
International analysis of mental health provision in eight G20 countries reveals stigma, a shortage of mental health professionals and inconsistent availability and quality of care are creating...
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
06 mai 2024 05h00 HE
|
Boehringer Ingelheim
Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic...
Less than half of veterinary professionals feel their profession is appreciated
25 avr. 2024 03h00 HE
|
Boehringer Ingelheim
World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated. Veterinary associations and...
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
16 avr. 2024 04h35 HE
|
Boehringer Ingelheim
Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV®Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launchesR&D expenditures increase by 14.2% to EUR 5.8...
SPEVIGO® approved for expanded indications in China and the US
19 mars 2024 07h00 HE
|
Boehringer Ingelheim
Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue1,2,3,4In China,...